Symbols / GANX
GANX Chart
About
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 105.39M |
| Enterprise Value | 90.71M | Income | -19.39M | Sales | — |
| Book/sh | 0.16 | Cash/sh | 0.24 | Dividend Yield | — |
| Payout | 0.00% | Employees | 23 | IPO | — |
| P/E | — | Forward P/E | -3.86 | PEG | — |
| P/S | — | P/B | 16.71 | P/C | — |
| EV/EBITDA | -5.17 | EV/Sales | — | Quick Ratio | 2.30 |
| Current Ratio | 2.52 | Debt/Eq | 10.24 | LT Debt/Eq | — |
| EPS (ttm) | -0.61 | EPS next Y | -0.71 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 16:00 | ROA | -86.79% |
| ROE | -261.72% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 38.46M |
| Shs Float | 34.84M | Short Float | 7.99% | Short Ratio | 2.81 |
| Short Interest | — | 52W High | 4.34 | 52W Low | 1.41 |
| Beta | 0.06 | Avg Volume | 1.31M | Volume | 2.93M |
| Target Price | $7.60 | Recom | None | Prev Close | $2.09 |
| Price | $2.74 | Change | 31.10% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.60
Mean price target
2. Current target
$2.74
Latest analyst target
3. DCF / Fair value
$-4.46
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.74
Low
$5.00
High
$10.00
Mean
$7.60
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-19 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-10-15 | reit | BTIG | Buy → Buy | $9 |
| 2025-10-13 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-10-07 | main | Maxim Group | Buy → Buy | $7 |
| 2025-09-08 | reit | BTIG | Buy → Buy | $9 |
| 2025-08-13 | main | Roth Capital | Buy → Buy | $6 |
| 2025-07-03 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-05-19 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-03-28 | main | Chardan Capital | Buy → Buy | $6 |
| 2025-03-17 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-03-07 | init | Scotiabank | — → Sector Outperform | $12 |
| 2024-12-24 | main | Roth MKM | Buy → Buy | $7 |
| 2024-12-05 | init | Roth MKM | — → Buy | $7 |
| 2024-11-25 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-10-09 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-10-01 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-09-03 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-08-09 | main | Chardan Capital | Buy → Buy | $6 |
| 2024-07-11 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-07-02 | main | HC Wainwright & Co. | Buy → Buy | $8 |
- Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy - Yahoo Finance Mon, 08 Dec 2025 08
- Parkinson’s patients see sharp drop in harmful brain marker in trial - Stock Titan ue, 06 Jan 2026 08
- BTIG Reiterates Gain Therapeutics (GANX) Buy Recommendation - Nasdaq Wed, 15 Oct 2025 07
- Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients - Seeking Alpha Fri, 07 Nov 2025 08
- Gain Therapeutics stock falls after announcing public offering - Investing.com ue, 15 Jul 2025 07
- Gain Therapeutics Reports First-Ever Reduction of Glucosylsphingosine in CSF of Parkinson's Disease Patients in Phase 1b Study of GT-02287 | GANX Stock News - Quiver Quantitative hu, 18 Dec 2025 08
- Gain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data - TipRanks hu, 18 Dec 2025 08
- Gain Therapeutics (GANX) Upgraded to Buy: Here's Why - Yahoo Finance Mon, 22 Dec 2025 08
- Gain Therapeutics At A Crossroads: Will GT-02287 Deliver Disease-Modifying Proof? - RTTNews Wed, 10 Dec 2025 08
- Gain Therapeutics' (GANX) Preclinical Momentum Drives Its Progress in Parkinson's Drug Development - Finviz Sat, 29 Nov 2025 08
- Gain Therapeutics (NASDAQ: GANX) completes Phase 1b enrollment of 21; extension approved - Stock Titan Wed, 12 Nov 2025 08
- Gain Therapeutics Sees Stock Surge Amid Positive Clinical Results and Ambitious Price Target Increase - StocksToTrade Sun, 21 Dec 2025 08
- Gain Therapeutics Announces Phase 1b Study Results for GT-02287 - TradingView hu, 18 Dec 2025 08
- Gain Therapeutics (GANX) Price Target Increased by 11.76% to 7.75 - Nasdaq Sat, 20 Dec 2025 08
- Gain Therapeutics Reports Positive Interim Data from Phase 1b Study of GT-02287 in Parkinson’s Disease - Quiver Quantitative Mon, 06 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 50000 | 49940.0 | — | Purchase at price 1.00 per share. | ISLAM KHALID | Officer and Director | — | 2024-08-09 00:00:00 | D |
| 1 | 14400 | 14544.0 | — | Purchase at price 1.01 per share. | MACK GENE C | Chief Executive Officer | — | 2024-08-09 00:00:00 | D |
| 2 | 17000 | 20670.0 | — | Purchase at price 1.21 - 1.23 per share. | RICHMAN ERIC I. | Director | — | 2024-07-01 00:00:00 | D |
| 3 | 30000 | 115770.0 | — | Purchase at price 3.86 per share. | RILEY JEFFREY SCOTT | Director | — | 2024-03-28 00:00:00 | D |
| 4 | 20212 | nan | — | — | ALDER MATTHIAS | Chief Executive Officer | — | 2024-03-26 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 25.02K | -90.16K | -509.19 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.01 | 0.00 |
| NormalizedEBITDA | -20.39M | -21.74M | -17.62M | -13.74M |
| TotalUnusualItems | 119.12K | -429.35K | -96.07K | -72.92K |
| TotalUnusualItemsExcludingGoodwill | 119.12K | -429.35K | -96.07K | -72.92K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -20.41M | -22.27M | -17.59M | -13.89M |
| ReconciledDepreciation | 84.07K | 83.58K | 64.17K | 15.48K |
| EBITDA | -20.27M | -22.17M | -17.71M | -13.81M |
| EBIT | -20.35M | -22.25M | -17.78M | -13.83M |
| NetInterestIncome | 357.10K | 494.23K | 375.36K | 12.49K |
| InterestIncome | 357.10K | 494.23K | 375.36K | |
| NormalizedIncome | -20.51M | -21.93M | -17.50M | -13.82M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -20.41M | -22.27M | -17.59M | -13.89M |
| TotalExpenses | 20.35M | 22.31M | 17.92M | 13.99M |
| TotalOperatingIncomeAsReported | -20.35M | -22.25M | -17.78M | -13.83M |
| DilutedAverageShares | 22.88M | 13.01M | 11.88M | 10.17M |
| BasicAverageShares | 22.88M | 13.01M | 11.88M | 10.17M |
| DilutedEPS | -0.89 | -1.71 | -1.48 | -1.37 |
| BasicEPS | -0.89 | -1.71 | -1.48 | -1.37 |
| DilutedNIAvailtoComStockholders | -20.41M | -22.27M | -17.59M | -13.89M |
| NetIncomeCommonStockholders | -20.41M | -22.27M | -17.59M | -13.89M |
| NetIncome | -20.41M | -22.27M | -17.59M | -13.89M |
| NetIncomeIncludingNoncontrollingInterests | -20.41M | -22.27M | -17.59M | -13.89M |
| NetIncomeContinuousOperations | -20.41M | -22.27M | -17.59M | -13.89M |
| TaxProvision | 536.82K | 79.28K | 92.98K | 4.01K |
| PretaxIncome | -19.87M | -22.19M | -17.50M | -13.89M |
| OtherIncomeExpense | 119.12K | -429.35K | -96.07K | -72.92K |
| GainOnSaleOfSecurity | 119.12K | -429.35K | -96.07K | -72.92K |
| NetNonOperatingInterestIncomeExpense | 357.10K | 494.23K | 375.36K | 12.49K |
| TotalOtherFinanceCost | -375.36K | -12.49K | ||
| InterestIncomeNonOperating | 357.10K | 494.23K | 375.36K | |
| OperatingIncome | -20.35M | -22.25M | -17.78M | -13.83M |
| OperatingExpense | 20.35M | 22.31M | 17.92M | 13.99M |
| ResearchAndDevelopment | 10.79M | 11.52M | 8.38M | 7.16M |
| SellingGeneralAndAdministration | 9.56M | 10.79M | 9.54M | 6.83M |
| GeneralAndAdministrativeExpense | 9.56M | 10.79M | 9.54M | 6.83M |
| OtherGandA | 9.56M | 10.79M | 9.54M | 6.83M |
| TotalRevenue | 0.00 | 55.18K | 140.11K | 164.99K |
| OperatingRevenue | 0.00 | 55.18K | 132.64K | 133.93K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 27.13M | 16.21M | 11.88M | 11.88M |
| ShareIssued | 27.13M | 16.21M | 11.88M | 11.88M |
| TotalDebt | 653.01K | 1.03M | 1.27M | 1.61M |
| TangibleBookValue | 7.21M | 12.38M | 18.67M | 34.61M |
| InvestedCapital | 7.78M | 13.15M | 19.48M | 35.51M |
| WorkingCapital | 7.69M | 12.83M | 16.97M | 35.17M |
| NetTangibleAssets | 7.21M | 12.38M | 18.67M | 34.61M |
| CapitalLeaseObligations | 214.51K | 459.55K | 670.86K | 914.19K |
| CommonStockEquity | 7.34M | 12.58M | 18.88M | 34.82M |
| TotalCapitalization | 7.67M | 13.03M | 19.37M | 35.41M |
| TotalEquityGrossMinorityInterest | 7.34M | 12.58M | 18.88M | 34.82M |
| StockholdersEquity | 7.34M | 12.58M | 18.88M | 34.82M |
| GainsLossesNotAffectingRetainedEarnings | -247.55K | 247.24K | 35.63K | -90.64K |
| OtherEquityAdjustments | -247.55K | 247.24K | 35.63K | -90.64K |
| RetainedEarnings | -81.19M | -60.78M | -38.52M | -20.93M |
| AdditionalPaidInCapital | 88.78M | 73.11M | 57.36M | 55.83M |
| CapitalStock | 2.71K | 1.62K | 1.19K | 1.19K |
| CommonStock | 2.71K | 1.62K | 1.19K | 1.19K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 4.78M | 6.03M | 5.22M | 4.17M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 872.99K | 1.08M | 1.09M | 1.61M |
| EmployeeBenefits | 443.62K | 307.45K | 157.58K | 329.46K |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 443.62K | 307.45K | 157.58K | 329.46K |
| NonCurrentDeferredLiabilities | 47.44K | 94.79K | 0.00 | |
| NonCurrentDeferredRevenue | 47.44K | 94.79K | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 381.93K | 678.91K | 937.04K | 1.29M |
| LongTermCapitalLeaseObligation | 53.60K | 229.85K | 441.78K | 695.05K |
| LongTermDebt | 328.33K | 449.05K | 495.26K | 590.47K |
| CurrentLiabilities | 3.91M | 4.95M | 4.13M | 2.55M |
| CurrentDeferredLiabilities | 270.70K | 1.17M | 162.49K | 266.88K |
| CurrentDeferredRevenue | 252.21K | 1.12M | 55.18K | 266.50K |
| CurrentDeferredTaxesLiabilities | 18.49K | 48.97K | 107.31K | 380.00 |
| CurrentDebtAndCapitalLeaseObligation | 271.09K | 348.49K | 337.21K | 322.96K |
| CurrentCapitalLeaseObligation | 160.91K | 229.69K | 229.08K | 219.14K |
| CurrentDebt | 110.18K | 118.80K | 108.14K | 103.83K |
| OtherCurrentBorrowings | 110.18K | 118.80K | 108.14K | 103.83K |
| CurrentProvisions | 380.00 | |||
| PayablesAndAccruedExpenses | 3.37M | 3.43M | 3.63M | 1.96M |
| CurrentAccruedExpenses | 2.19M | 1.74M | 1.74M | 1.15M |
| Payables | 1.18M | 1.69M | 1.88M | 815.55K |
| OtherPayable | 229.32K | 368.35K | 256.80K | 255.07K |
| AccountsPayable | 946.26K | 1.32M | 1.63M | 560.48K |
| TotalAssets | 12.12M | 18.61M | 24.10M | 38.99M |
| TotalNonCurrentAssets | 521.41K | 830.46K | 3.01M | 1.26M |
| OtherNonCurrentAssets | 63.80K | 51.91K | 48.32K | 53.39K |
| NonCurrentPrepaidAssets | 22.11K | |||
| InvestmentsAndAdvances | 0.00 | 1.94M | 0.00 | |
| InvestmentinFinancialAssets | 0.00 | 1.94M | 0.00 | |
| AvailableForSaleSecurities | 1.94M | |||
| GoodwillAndOtherIntangibleAssets | 134.27K | 193.38K | 213.97K | 202.61K |
| OtherIntangibleAssets | 134.27K | 193.38K | 213.97K | 202.61K |
| NetPPE | 323.33K | 585.18K | 804.31K | 1.01M |
| AccumulatedDepreciation | -123.36K | -92.80K | -53.33K | -28.39K |
| GrossPPE | 446.69K | 677.97K | 857.64K | 1.04M |
| Leases | 31.62K | 33.99K | 31.44K | 17.33K |
| OtherProperties | 255.41K | 497.26K | 696.83K | 920.80K |
| MachineryFurnitureEquipment | 159.66K | 146.72K | 129.38K | 97.29K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 11.60M | 17.78M | 21.09M | 37.72M |
| CurrentDeferredAssets | 0.00 | |||
| RestrictedCash | 0.00 | |||
| PrepaidAssets | 450.85K | 741.64K | 761.42K | 645.92K |
| Receivables | 765.76K | 242.58K | 191.31K | 195.45K |
| OtherReceivables | 494.68K | 87.43K | 81.86K | |
| TaxesReceivable | 271.08K | 242.58K | 103.88K | 113.59K |
| AccountsReceivable | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 10.39M | 16.79M | 20.14M | 36.88M |
| OtherShortTermInvestments | 0.00 | 5.00M | 12.83M | 0.00 |
| CashAndCashEquivalents | 10.39M | 11.79M | 7.31M | 36.88M |
| CashEquivalents | 4.75M | 6.77M | 4.40M | 33.62M |
| CashFinancial | 5.64M | 5.03M | 2.91M | 3.26M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -18.90M | -18.88M | -14.81M | -12.46M |
| RepaymentOfDebt | -90.88K | -89.07K | -78.77K | -21.95K |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 13.21M | 12.73M | 0.00 | 42.63M |
| CapitalExpenditure | -22.49K | -15.36K | -118.95K | -94.21K |
| IncomeTaxPaidSupplementalData | 86.31K | 134.96K | 2.74K | 4.47K |
| EndCashPosition | 10.42M | 11.83M | 7.34M | 36.91M |
| BeginningCashPosition | 11.83M | 7.34M | 36.91M | 7.50M |
| EffectOfExchangeRateChanges | -527.17K | 488.40K | -23.80K | 100.78K |
| ChangesInCash | -884.24K | 4.00M | -29.55M | 29.31M |
| FinancingCashFlow | 13.01M | 12.64M | -78.77K | 41.77M |
| CashFlowFromContinuingFinancingActivities | 13.01M | 12.64M | -78.77K | 41.77M |
| NetOtherFinancingCharges | -280.87K | -853.49K | ||
| ProceedsFromStockOptionExercised | 171.51K | 0.00 | 0.00 | 12.22K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 13.21M | 12.73M | 0.00 | 42.63M |
| CommonStockIssuance | 13.21M | 12.73M | 0.00 | 42.63M |
| NetIssuancePaymentsOfDebt | -90.88K | -89.07K | -78.77K | -21.95K |
| NetLongTermDebtIssuance | -90.88K | -89.07K | -78.77K | -21.95K |
| LongTermDebtPayments | -90.88K | -89.07K | -78.77K | -21.95K |
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 4.98M | 10.22M | -14.77M | -94.21K |
| CashFlowFromContinuingInvestingActivities | 4.98M | 10.22M | -14.77M | -94.21K |
| NetInvestmentPurchaseAndSale | 5.00M | 10.24M | -14.66M | 0.00 |
| SaleOfInvestment | 5.00M | 12.19M | 3.08M | 0.00 |
| PurchaseOfInvestment | 0.00 | -1.96M | -17.74M | 0.00 |
| NetPPEPurchaseAndSale | -22.49K | -15.36K | -118.95K | -94.21K |
| PurchaseOfPPE | -22.49K | -15.36K | -118.95K | -94.21K |
| OperatingCashFlow | -18.87M | -18.87M | -14.69M | -12.37M |
| CashFlowFromContinuingOperatingActivities | -18.87M | -18.87M | -14.69M | -12.37M |
| ChangeInWorkingCapital | -1.08M | 442.23K | 1.51M | -329.78K |
| ChangeInOtherWorkingCapital | -977.63K | 1.09M | -149.65K | 90.03K |
| ChangeInOtherCurrentLiabilities | -50.53K | 711.07K | 665.46K | |
| ChangeInPayablesAndAccruedExpense | 274.89K | -693.70K | 1.07M | -521.39K |
| ChangeInPayable | 274.89K | -693.70K | 1.07M | -521.39K |
| ChangeInAccountPayable | 274.89K | -693.70K | 1.07M | -521.39K |
| ChangeInPrepaidAssets | -377.65K | 44.32K | -116.91K | -500.52K |
| ChangeInReceivables | -130.07K | 3.63K | -63.35K | |
| ChangesInAccountReceivables | 0.00 | 8.26K | ||
| OtherNonCashItems | 143.52K | -383.19K | -206.86K | -34.13K |
| StockBasedCompensation | 2.39M | 3.26M | 1.53M | 839.37K |
| DepreciationAmortizationDepletion | 84.07K | 83.58K | 64.17K | 15.48K |
| DepreciationAndAmortization | 84.07K | 83.58K | 64.17K | 15.48K |
| Depreciation | 15.48K | |||
| OperatingGainsLosses | 1.03M | |||
| PensionAndEmployeeBenefitExpense | 55.33K | |||
| GainLossOnInvestmentSecurities | 1.03M | |||
| NetIncomeFromContinuingOperations | -20.41M | -22.27M | -17.59M | -13.89M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for GANX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|